Fangfang Lv

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Li Jin, Xinmin Zhao, Lei Chen et al. · BMC Cancer · 2010 · 273 citations · Full text

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Clinical Cancer Research · 2020 · 176 citations

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Yuqin Song, Quanli Gao, Huilai Zhang et al. · Leukemia · 2019 · 153 citations · Full text

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Yuqin Song, Keshu Zhou, Dehui Zou et al. · Blood · 2022 · 143 citations · Full text

Long-term Efficacy, Pathology, Pharmacotherapy +17

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Matthew J. Matasar, Marcelo Capra, Muhıt Özcan et al. · The Lancet Oncology · 2021 · 132 citations · Full text

Lymphoid Neoplasia, Medicine, Pharmacology +7